Pharmatest’s crowded scientific event calendar


Pharmatest’s crowded scientific event calendar


Pharmatest Logo

Press Release | Pharmatest Services Ltd

MARCH 31, 2015

Turku, Finland: – Pharmatest Services, the contract research organization that specializes in preclinical efficacy services in oncology and skeletal diseases, has an exceptionally full event schedule for 2015.

Altogether, Pharmatest will attend at least 12 meetings and conferences during the year, including five in just over a month.

Starting with this week’s appearance at the EAU Congress in Madrid (March 20-24) the next event will be the two day annual meeting of the Massachusetts Biotechnology Council (MassBio) in Cambridge.

Scientific papers

Staying in the USA, Pharmatest will also be present from April 18 to 22at the prestigious Annual Meeting of the American Association for Cancer Research(AACR) in Philadelphia, where it will be an exhibitor as well as presenting three scientific papers with implications for prostate cancer and multiple myeloma therapy.

The AACR meeting will be the start of an exceptionally crowded fortnight for Pharmatest, with four events in 14 days. Three days after AACR 2015 closes, Pharmatest will attend the fourth Joint Meeting of the European Calcified Tissue Society (ECTS) and the International Bone and Mineral Society (IBMS) in Rotterdam, The Netherlands, starting on April 25.

The next meeting will be again in USA, the Osteoarthritis Research Society International (OARSI) World Congress in Seattle on April 30. After that the schedule becomes a little less hectic, with a month before Pharmatest’s next event appearance at the Scand-LAS Annual Meeting from June 9 to June 12in Pharmatest’s own hometown of Turku in Finland.

In July, Pharmatest will be back on Boston for two events happening almost concurrently: the Tumor Models conference between July 21 and 23 and the Drug Discovery and Therapy World Congress 2015, running July 22-25.

Events schedule

All of Pharmatest’s forthcoming 2015 events are listed below, together with links to resources for more information.

Event Date Place More information
MassBio Annual meeting March 26-27 Boston, USA http://www.massbio.org
AACR Annual Meeting (Booth #1641) April 18-22 Philadelphia, USA http://www.aacr.org
ECTS-IBMS-CIBD April 25-28 Rotterdam, The Netherlands http://www.ects-ibms2015.org
OARSI 2015 World Congress April 30 – May 3 Seattle, USA http://2015.oarsi.org
Scand-LAS Annual Meeting June 9-12 Turku, Finland http://congress.utu.fi/scandlas2015/
Drug Discovery and Therapy World Congress 2015 July 22-25 Boston, USA http://www.ddtwc.com
Tumor Models Boston 2015 July 21-23 Boston, USA http://tumor-models.com
ASBMR 2015 Annual Meeting Oct. 9-12 Seattle, USA http://www.asbmr.org/annual-meeting
AACR-NCI-EORTC: International Conference on Molecular Targets and Cancer Therapeutics Nov. 5-9 Boston, USA http://www.aacr.org
 

About Pharmatest

Pharmatest Services Ltd (Pharmatest) is a contract research organisation (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.

The CRO has supported close to 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.

Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.

Media Contacts

Jussi Halleen; CEO, Pharmatest Services Ltd.
Tel.: + 358 50 380 9551
Email: jussi.halleen@pharmatest.com

Resources

Click on Pharmatest’s crowded scientific event calendar for other information.
Click on Pharmatest to contact the company directly.


Supplier Information
Supplier: Pharmatest Services Ltd
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com


Comments are closed.